Loading...
•
Sep 30, 2021
Taysha Gene Therapies Q3 2021 Earnings Report
Taysha Gene Therapies reported financial results for the third quarter of 2021 and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $51.2 million for Q3 2021. The company made significant advances across multiple programs, including regulatory meetings and preclinical data publications.
Submitted an end-of-Phase meeting request for TSHA-120 with a major ex-US regulatory agency.
Expect to report clinical safety and functional MFM32 data for TSHA-120 from the high dose cohort in December.
Remain on track to report preliminary clinical safety data and Hex A enzyme activity for TSHA-101 in December.
Anticipate preliminary clinical data for the first-generation construct in CLN7 disease in December.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha Gene Therapies anticipates several milestones across its programs and expects to provide updates throughout the remainder of the year.
Positive Outlook
- Anticipate clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort in GAN in December 2021.
- Expect preliminary clinical safety data and Hex A enzyme activity for TSHA-101 in GM2 gangliosidosis in December 2021.
- Anticipate preliminary clinical data for the first-generation construct in CLN7 disease in December 2021.
- On track to initiate Phase 1/2 trials for TSHA-118 in CLN1 disease and TSHA-102 in Rett syndrome by year-end 2021.
- Expect to finalize the second-generation CLN7 construct by year-end and initiate a planned pivotal clinical trial in 2022 with reference to clinical data from the first-generation construct.